Deodorant sold by Walmart, Amazon recalled nationwide
According to an FDA enforcement report, A.P. Deauville initiated the recall on July 10 for 67,214 cases of Power Stick for Her roll-on Antiperspirant Deodorant Powder Fresh, Power Stick Invisible Protection Roll-On Antiperspirant Deodorant Spring Fresh and Power Stick Original Nourishing Invisible Protection Roll-On Antiperspirant Deodorant.
The lot numbers of the recalled deodorant, according to the report, are:
Power Stick for Her Roll-On: 032026B011, 032226B031, 051626C241, 061526C882, 071226D371, 071226D381, 082526E341 and 082826E402.
Power Stick Invisible Protection Roll-On: 031726A991, 041226B561, 062026C901, 062026C911, 071026D351, 071026D361, 071326D391 and 111626G231.
Power Stick Original Nourishing Invisible Protection Roll-On: 101225D781, 032926B281, 032826B221, 041126B531, 062226D011, 070626D301, 070626D333, 111026G051, 111326G091 and 111626G221.
The antiperspirants were distributed nationwide and sold at Walmart, Amazon and Dollar Tree.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
21 minutes ago
- Yahoo
US health officials crack down on kratom-related products after complaints from supplement industry
WASHINGTON (AP) — U.S. health officials are warning Americans about the risks of an opioid-related ingredient increasingly added to energy drinks, gummies and supplements sold at gas stations and convenience stores, recommending a nationwide ban. The chemical, known as 7- hydroxymitragynine, is a component of kratom, a plant native to Southeast Asia that has gained popularity in the U.S. as an unapproved treatment for pain, anxiety and drug dependence. In recent months, dietary supplement companies that sell kratom have been urging the Food and Drug Administration to crack down on the products containing 7-OH, portraying it as a dangerously concentrated, synthetic form of the original ingredient. The FDA action 'is not focused on natural kratom leaf products," according to a statement Tuesday by the U.S. Department of Health and Human Services. The agency said it was releasing a report to educate about the risks of '7-OH and its distinction from the kratom plant leaf.' Regulators are also recommending that the ingredient be placed on the federal government's most restrictive list of illegal drugs, which includes LSD and heroin. '7-OH is an opioid that can be more potent than morphine," said FDA Commissioner Marty Makary. "We need regulation and public education to prevent another wave of the opioid epidemic.' The agency's recommendation will be reviewed by the Drug Enforcement Administration, which sets federal rules for high-risk drugs including prescription medicines and illicit substances. A national ban wouldn't take effect until the agency drafts and finalizes new rules governing the ingredient. Federal regulators have been scrutinizing kratom for about a decade after reports of addiction, injury and overdose. But users and distributors have long opposed efforts to regulate it, saying kratom could be a safer alternative to opioid painkillers that sparked the ongoing drug addiction epidemic. Last month, the FDA issued warning letters to seven companies selling drinks, gummies and powders infused with 7-OH. Regulators said the products violated FDA rules because they have not been evaluated for safety and, in some cases, claimed to treat medical conditions, including pain, arthritis and anxiety. Supplement executives quickly applauded the move. The FDA "demonstrated the exact kind of data-driven, proactive regulatory excellence needed to safeguard unwitting consumers across the U.S.,' said Ryan Niddel of Diversified Botanics, a Utah-based company that sells kratom supplements. An industry group, the American Kratom Association, has lobbied Congress for years against restrictions on the plant. Legislation supported by the group would prohibit the FDA from regulating kratom more strictly than food and dietary supplements. In recent years, the association has lobbied at the state level for bills that limit synthetic 7-OH products. On Tuesday, a rival group that supports the availability of 7-OH drugs criticized the government's move, pointing to the influence of kratom suppliers. 'Big kratom trade groups have spent years blaming 7-OH for harms caused by their own unregulated products, because it threatens their market share,' the Holistic Alternative Recovery Trust stated in an emailed message. Nearly a decade ago, the federal government came close to banning kratom. In 2016, the DEA announced plans to add it to the government's most restrictive schedule 1, reserved for drugs that have no medical use and a high potential for abuse. But the plan stalled after a flood of public complaints, including a letter signed by more than 60 members of Congress. The FDA then began studying the ingredient, concluding in 2018 that kratom contains many of the same chemicals as opioids, the addictive class of drugs that includes painkillers like OxyContin as well as heroin and fentanyl. Since then, FDA regulators have continued to issue warnings about cases of injury, addiction and death with kratom supplements, which are usually sold in capsules or powders. In recent months, the FDA has also issued warnings on other unapproved drugs sold as supplements or energy drinks, including the antidepressant tianeptine. Sometimes referred to collectively as 'gas station heroin,' the drugs have been restricted by several states, but they are not scheduled at the federal level. ___ The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Department of Science Education and the Robert Wood Johnson Foundation. The AP is solely responsible for all content. Matthew Perrone, The Associated Press
Yahoo
an hour ago
- Yahoo
EuMentis Therapeutics Receives U.S. FDA Clearance of IND Application for EM-221, a Novel PDE10A Inhibitor for Schizophrenia
-Company expects to initiate Phase 2 study in 2H 2025- SAN DIEGO, July 30, 2025 /PRNewswire/ -- EuMentis Therapeutics, Inc., ("EuMentis"), a clinical-stage drug development company focused on advancing novel treatments for schizophrenia and other central nervous system (CNS) conditions, today announced that the U.S. Food and Drug Administration (FDA) has authorized its Investigational New Drug (IND) application to initiate a Phase 2 clinical trial of EM–221, the company's investigational phosphodiesterase 10A (PDE10A) inhibitor, in patients with schizophrenia. "This IND clearance represents a major milestone for EuMentis as we advance EM–221 through Phase 2 clinical development," said Frank Stonebanks, Chief Executive Officer of EuMentis. "EM–221 is more than a single asset—it represents a pipeline in a product with potential applications across multiple neuropsychiatric and neurodevelopmental conditions. As we enter this next phase, we're excited by the opportunity to unlock significant therapeutic and commercial value in schizophrenia and beyond, supported by a world-class team and leading scientific collaborators." EM-221 is targeting PDE10A, a key intracellular enzyme that regulates dopamine and glutamate signaling in brain regions implicated in schizophrenia. Unlike traditional antipsychotics that broadly block dopamine receptors and are associated with serious side effects such as weight gain, movement disorders, and sedation, PDE10A inhibition offers a more targeted mechanism that modulates these pathways without direct receptor antagonism. "We are very excited to receive IND clearance from the FDA for schizophrenia, which is a serious, lifelong disorder affecting nearly 4 million adults and adolescents in the U.S. alone," said Dr. Randall Marshall, Chief Medical Officer of EuMentis. "There is a wealth of data suggesting that a PDE10A inhibitor can benefit individuals with schizophrenia as a more effective, safer, and better-tolerated therapy. We look forward to initiating our Phase 2 study of EM-221 later this year." EM–221 is a next-generation, selective PDE10A inhibitor designed to maximize efficacy while minimizing off-target effects. Preclinical and phase 1 clinical studies suggest EM–221 may offer superior tolerability and a broader therapeutic window, positioning it as a potential best-in-class treatment for both the positive and negative symptoms of schizophrenia—a critical gap left unaddressed by current therapies. "Despite decades of use, current dopamine receptor-blocking antipsychotic medications remain limited in their tolerability and effectiveness which make them unacceptable to many patients," said Dr. John Krystal, Robert L. McNeil, Jr. Professor of Translational Research and Chair of Psychiatry at Yale School of Medicine. "The PDE10A mechanism represents an important and innovative approach to modulating dopaminergic and glutamatergic signaling in the brain. I'm encouraged by the potential of EM–221 to offer a new therapeutic option for patients who urgently need safer and more effective treatments." About EM-221 EuMentis is building a pipeline-in-a-product around EM-221. EM-221 is an innovative product that targets the phosphodiesterase 10A enzyme, uniquely concentrated in the brain's striatum, to enhance cyclic nucleotide signaling and balance dopamine pathways. Unlike traditional antipsychotics, it offers the potential to address not only the positive symptoms like hallucinations but also the challenging negative symptoms—such as social withdrawal, blunted emotions and difficulty planning—that often persist untreated. EM-221 has been cleared by the U.S. FDA for Phase 2 evaluation, and the company expects to begin dosing in its first clinical trial in the second half of 2025. About EuMentis Therapeutics EuMentis is a clinical-stage drug development company focused on advancing novel treatments for schizophrenia and other central nervous system (CNS) conditions. EuMentis is committed to leading innovation in the neuropsychiatric disease field by advancing programs that target selective CNS circuits in the brain with clinically validated mechanisms of action. This approach will enable its therapies to achieve better efficacy and tolerability, with the goal to deliver improved outcomes for patients. The Company's lead product, EM-221, is a potentially groundbreaking advancement in schizophrenia treatment, with a new, differentiated PDE10A inhibitor. Developed through years of rigorous research, this breakthrough heralds a new era of hope, aiming to improve overall quality of life for those affected by schizophrenia with a novel mechanism that's both precise and promising. EuMentis is headquartered in San Diego, CA. For more information, please visit and engage with us on LinkedIn. Media ContactAmy ConradJuniper Pointamy@ Company ContactFrank StonebanksCEOfstonebanks@ View original content to download multimedia: SOURCE EuMentis Therapeutics, Inc. Sign in to access your portfolio
Business Wire
an hour ago
- Business Wire
QualiZeal Welcomes Healthcare Industry Visionary Dr. Aiman Abdel-Malek to Business Advisory Board
DALLAS--(BUSINESS WIRE)--QualiZeal Inc., the world's fastest-growing Quality Engineering (QE) services company, announced the appointment of renowned healthcare industry visionary Dr. Aiman Abdel-Malek to its Business Advisory Board. This strategic move aims to leverage Dr. Abdel-Malek's transformative leadership experience in the healthcare, life sciences, and medical devices sectors as QualiZeal fortifies its position as a leader in the enterprise digital transformation landscape. With more than 25 years in executive leadership roles at GE, Qualcomm, and Insulet Corporation, Dr. Abdel-Malek is a recognized expert in secure, connected diabetes management systems and mobile healthcare solutions. Under his distinguished leadership, Insulet launched the world's first FDA-cleared, smartphone-controlled tubeless insulin patch pump and artificial pancreas. With over 40 patents and publications in secure connected healthcare, digital care delivery, and safe AI, he serves as a board advisor to several companies driving personalized healthcare innovation through digital technology and AI. "Welcoming Dr. Aiman Abdel-Malek to our Business Advisory Board is a tremendous honor," said Kalyan Konda, Co-Founder, Executive Director, and CEO of QualiZeal. "His proven track record in AI-driven healthcare breakthroughs will provide invaluable strategic guidance as we solidify our market leadership and advance toward our goal of quadrupling the company by 2028. Dr. Abdel-Malek's strategic counsel will be crucial in shaping our next generation of innovation, expanding our global impact, and solidifying our position as a leader in modern quality engineering." Dr. Aiman Abdel-Malek shared his enthusiasm about the partnership, stating, 'I believe QualiZeal will redefine how Quality Engineering is being practiced. The highly innovative, patent-pending QMentisAI platform is truly a game-changer. It's the industry's most complete end-to-end GenAI-powered QE platform, dramatically accelerating the journey from functional requirements to automated testing with regulatory-grade precision, reducing process times by over 60%. Backed by visionary leadership and a world-class team, QualiZeal has the clarity, innovation, and momentum to lead the industry. I'm proud to join them on this exciting journey.' About QualiZeal: QualiZeal is the world's fastest-growing Quality Engineering (QE) services company, known for its automation-first, AI-led, and platform-driven approach to software quality. With a diverse portfolio of digital transformation services—including Quality Engineering, Digital Engineering, Advisory & Transformation, and Emerging Technology Testing—QualiZeal empowers leading global organizations to achieve quality excellence and sustainable market leadership. QualiZeal's award-winning proprietary platforms, QMentisAI (patent-pending) and QualiCentral, pioneer the innovative use of AI and GenAI to solve complex QE challenges at speed and scale for clients in their digital transformation journeys. Recognized by Gartner, Everest Group, Forrester, Frost & Sullivan, and NelsonHall, the company has received numerous accolades, including the 2025 Gold Stevie® Award for Fastest Growing Tech Company of the Year (American Business Awards®). Trusted by 70+ global enterprise clients and backed by 850+ elite quality engineers, QualiZeal drives seamless digital transformation—reflected in its industry-leading Net Promoter Score (NPS) of 75. For more information, please visit
